BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang MY, Zhu GQ, Shi KQ, Zheng JN, Cheng Z, Zou ZL, Huang HH, Chen FY, Zheng MH. Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget. 2016;7:30642-30658. [PMID: 27121321 DOI: 10.18632/oncotarget.8907] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Alsunaid SR, Ashraf H, Soubani AO. Tenofovir alafenamide associated fatal lactic acidosis in an autologous hematopoietic stem cell transplant recipient. Transpl Infect Dis 2018;20:e12960. [PMID: 29975806 DOI: 10.1111/tid.12960] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Blackard JT, Sherman KE. Hepatitis B virus (HBV) reactivation-The potential role of direct-acting agents for hepatitis C virus (HCV). Rev Med Virol 2018;28:e1984. [PMID: 29761585 DOI: 10.1002/rmv.1984] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Rivera D, Ferrajoli A. Managing the Risk of Infection in Chronic Lymphocytic Leukemia in the Era of New Therapies. Curr Oncol Rep 2022. [PMID: 35366167 DOI: 10.1007/s11912-022-01261-9] [Reference Citation Analysis]
5 Wang G, Duan Z. Guidelines for Prevention and Treatment of Chronic Hepatitis B. J Clin Transl Hepatol 2021;9:769-91. [PMID: 34722192 DOI: 10.14218/JCTH.2021.00209] [Reference Citation Analysis]
6 Picardi M, Della Pepa R, Giordano C, Zacheo I, Pugliese N, Mortaruolo C, Trastulli F, Giordano A, Lucignano M, Di Perna M, Raimondo M, Salvatore C, Pane F. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood 2019;133:498-501. [PMID: 30530802 DOI: 10.1182/blood-2018-10-878892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cheung CKM, Law MF, Chao DC, Wong SH, Ho R, Chao ACW, Lai JWY, Chan TYT, Tam MTK, Lau SLF, Tam THC. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis. J Dig Dis 2020;21:160-9. [PMID: 32040243 DOI: 10.1111/1751-2980.12848] [Reference Citation Analysis]
8 Morillas RM, López Sisamón D. Reactivación de la hepatitis B asociada a agentes inmunodepresores y a quimioterapia. Historia natural, factores de riesgo y recomendaciones para prevenirla. Medicina Clínica 2019;152:107-14. [DOI: 10.1016/j.medcli.2018.08.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Lee HM, Banini BA. Updates on Chronic HBV: Current Challenges and Future Goals. Curr Treat Options Gastro 2019;17:271-91. [DOI: 10.1007/s11938-019-00236-3] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 9.0] [Reference Citation Analysis]
10 Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560-1599. [PMID: 29405329 DOI: 10.1002/hep.29800] [Cited by in Crossref: 1129] [Cited by in F6Publishing: 998] [Article Influence: 282.3] [Reference Citation Analysis]
11 Coluccio C, Begini P, Marzano A, Pellicelli A, Imperatrice B, Anania G, Delle Fave G, Marignani M. Hepatitis B in patients with hematological diseases: An update. World J Hepatol 2017; 9(25): 1043-1053 [PMID: 28951776 DOI: 10.4254/wjh.v9.i25.1043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
12 Kim HY, Yoo JJ, Oh S, Yu SJ, Kim YJ, Yoon JH, Kim W, Jung YJ, Kim BH, Kim CM, Park JW, Lee JH. Scoring system for risk stratification of viral reactivation during prophylactic antiviral treatment in Korean patients with hepatitis B undergoing anticancer chemotherapy: A multicenter study. J Med Virol. 2018;90:1593-1603. [PMID: 29900560 DOI: 10.1002/jmv.25241] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang M, Gao F, Peng L, Shen L, Zhao P, Ni B, Hou J, Huang H. Distinct clinical features and prognostic factors of hepatitis C virus-associated non-Hodgkin's lymphoma: a systematic review and meta-analysis. Cancer Cell Int 2021;21:524. [PMID: 34627251 DOI: 10.1186/s12935-021-02230-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Gao F, Lin MS, You JS, Zhang MY, Cheng L, Lin K, Zhao P, Chen QY. Long-term outcomes of busulfan plus melphalan-based versus melphalan 200 mg/m2 conditioning regimens for autologous hematopoietic stem cell transplantation in patients with multiple myeloma: a systematic review and meta-analysis. Cancer Cell Int 2021;21:601. [PMID: 34758834 DOI: 10.1186/s12935-021-02313-z] [Reference Citation Analysis]
16 Yoon EL. [Prophylactic Antiviral Treatment in Immunosuppressed Chronic Hepatitis B Patients]. Korean J Gastroenterol 2019;74:258-66. [PMID: 31765554 DOI: 10.4166/kjg.2019.74.5.258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
17 Sagnelli C, Sica A, Creta M, Borsetti A, Ciccozzi M, Sagnelli E. Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19. Pathogens 2022;11:567. [DOI: 10.3390/pathogens11050567] [Reference Citation Analysis]
18 Sundaram S, Patil P, Sengar M, Rathod R, Mehta S. A survey of clinical practices among oncologists regarding hepatitis B screening in patients with cancer. Indian J Med Res 2020;151:604-8. [PMID: 32719235 DOI: 10.4103/ijmr.IJMR_2327_18] [Reference Citation Analysis]
19 Lazzari G, De Cillis MA, Buccoliero G, Silvano G. Competing Morbidities In Advanced Head And Neck Squamous Cell Carcinoma Concurrent Chemoradiotherapy: A Strong Implication Of A Multidisciplinary Team Approach. Cancer Manag Res 2019;11:9771-82. [PMID: 31819615 DOI: 10.2147/CMAR.S229524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Shih CA, Chen WC. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World J Clin Cases 2021; 9(21): 5769-5781 [PMID: 34368296 DOI: 10.12998/wjcc.v9.i21.5769] [Reference Citation Analysis]
21 Nicastro E, Norsa L, Di Giorgio A, Indolfi G, D'Antiga L. Breakthroughs and challenges in the management of pediatric viral hepatitis. World J Gastroenterol 2021; 27(20): 2474-2494 [PMID: 34092970 DOI: 10.3748/wjg.v27.i20.2474] [Reference Citation Analysis]
22 Wang J, Xu H, Liu P, Li M. Network meta-analysis of success rate and safety in antibiotic treatments of bronchitis. Int J Chron Obstruct Pulmon Dis 2017;12:2391-405. [PMID: 28848340 DOI: 10.2147/COPD.S139521] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B. Management of Hepatitis B Virus Infection and Prevention of Hepatitis B Virus Reactivation in Children With Acquired Immunodeficiencies or Undergoing Immune Suppressive, Cytotoxic, or Biological Modifier Therapies. J Pediatr Gastroenterol Nutr. 2020;70:527-538. [PMID: 31977956 DOI: 10.1097/mpg.0000000000002628] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
24 Zou X, Guo L, Gu Y, Yang Z, Huang P, Liu T, Zhao J, Wu G. Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy. J Cancer 2020;11:3559-66. [PMID: 32284752 DOI: 10.7150/jca.40154] [Reference Citation Analysis]
25 Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open 2021;5:1085-91. [PMID: 34584979 DOI: 10.1002/jgh3.12636] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Morales MR, Sendra C, Romero-Gomez M. Hepatitis B and NAFLD: Lives Crossed. Ann Hepatol 2017;16:185-7. [PMID: 28233740 DOI: 10.5604/16652681.1231556] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 Li FC, Li YK, Fan YC. Biomarkers for hepatitis B virus replication: an overview and a look to the future. Expert Rev Gastroenterol Hepatol 2020;14:1131-9. [PMID: 32887529 DOI: 10.1080/17474124.2020.1815530] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lin M, Zhang S, Zhang M, Shi J, Zhang C, Luo R, You J, Sun J, Zhang J, Gao F. Therapeutic efficacy and safety of Kangfuxin in combination with rabeprazole in the treatment of peptic ulcer: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23103. [PMID: 33235070 DOI: 10.1097/MD.0000000000023103] [Reference Citation Analysis]
29 Huang W, Du L, Tang H. Hepatitis B virus reactivation: overview and management. Future Virology 2021;16:821-35. [DOI: 10.2217/fvl-2021-0275] [Reference Citation Analysis]
30 Zhang MY, Gao F, Zhao YW, Ni BW, Huang HH, Hou J. Inferior survival and frequent hepatic dysfunction in non-Hodgkin's lymphoma patients with HBV infection: a systematic review and meta-analysis. Hematology 2022;27:70-9. [PMID: 34957924 DOI: 10.1080/16078454.2021.2011546] [Reference Citation Analysis]
31 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology. 2017;152:1297-1309. [PMID: 28219691 DOI: 10.1053/j.gastro.2017.02.009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 214] [Article Influence: 48.2] [Reference Citation Analysis]
32 Huang SC, Yang HC, Kao JH. Hepatitis B reactivation: diagnosis and management. Expert Rev Gastroenterol Hepatol 2020;14:565-78. [PMID: 32448008 DOI: 10.1080/17474124.2020.1774364] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
33 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]
34 Cao X, Wang Y, Li P, Huang W, Lu X, Lu H. HBV Reactivation During the Treatment of Non-Hodgkin Lymphoma and Management Strategies. Front Oncol 2021;11:685706. [PMID: 34277431 DOI: 10.3389/fonc.2021.685706] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
35 Liu Z, Jiang L, Liang G, Song E, Jiang W, Zheng Y, Gong C. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta-analysis of prophylaxis management. J Viral Hepat 2017;24:561-72. [PMID: 28072494 DOI: 10.1111/jvh.12672] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
36 Tsai YF, Hsu CM, Hsiao HH. Management of Hepatitis B Virus Reactivation in Malignant Lymphoma Prior to Immunosuppressive Treatment. J Pers Med 2021;11:267. [PMID: 33918206 DOI: 10.3390/jpm11040267] [Reference Citation Analysis]
37 Zhang D, Wu J, Wang K, Duan X, Liu S, Zhang B. Which are the best Chinese herbal injections combined with XELOX regimen for gastric cancer?: A PRISMA-compliant network meta-analysis. Medicine (Baltimore) 2018;97:e0127. [PMID: 29561411 DOI: 10.1097/MD.0000000000010127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
38 Toka B, Koksal AS, Eminler AT, Tozlu M, Uslan MI, Parlak E. Comparison of Tenofovir Disoproxil Fumarate and Entecavir in the Prophylaxis of HBV Reactivation. Dig Dis Sci 2021;66:2417-26. [PMID: 32729014 DOI: 10.1007/s10620-020-06506-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
39 Buti M, Manzano ML, Morillas RM, García-Retortillo M, Martín L, Prieto M, Gutiérrez ML, Suárez E, Gómez Rubio M, López J, Castillo P, Rodríguez M, Zozaya JM, Simón MA, Morano LE, Calleja JL, Yébenes M, Esteban R. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017;12:e0184550. [PMID: 28898281 DOI: 10.1371/journal.pone.0184550] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 6.6] [Reference Citation Analysis]